<DOC>
	<DOCNO>NCT02228850</DOCNO>
	<brief_summary>The purpose study evaluate pharmacodynamics ( PD ) adult subject diagnosis Raynaud 's Phenomenon secondary Systemic Sclerosis ( SSc ) .</brief_summary>
	<brief_title>Study Acute Peripheral Vascular Effects , Safety Tolerability Subjects With Raynaud 's Phenomenon Secondary Systemic Sclerosis</brief_title>
	<detailed_description>The purpose study evaluate pharmacodynamic ( PD ) effect topical Alprostadil digital perfusion laser Doppler capillary velocimetry digital temperature recovery thermography follow standardized cold challenge ass safety tolerability 3 dos Alprostadil topical cream placebo cream adult subject diagnosis Raynaud 's Phenomenon secondary Systemic Sclerosis ( SSc ) .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Raynaud Disease</mesh_term>
	<mesh_term>Alprostadil</mesh_term>
	<criteria>Subjects diagnosis SSc current ACR/EULAR Classification Criteria ; Evidence ongoing activity Raynaud 's Phenomenon measure Raynaud Condition Score 3 great Screening ; All female childbearing potential must negative serum pregnancy test ; . Females childbearing potential must abstain sexual activity could result pregnancy , agree use acceptable method contraception throughout study period 30 day follow dose investigational study drug . Acceptable contraception include : 1 . Intrauterine device 2 . Double barrier method ( e.g . condom diaphragm spermicidal gel foam ) 3 . Condom use advise form contraception Must willing able discontinue ongoing therapy RP least 72 hour prior application study medication ; drug include calcium channel blocker , angiotensinconverting enzyme ( ACE ) inhibitor , shortacting PDE5i ( sildenafil , vardenafil , avanafil ) , sympatholytics topical systemic nitrate ; Must willing able discontinue consumption caffeinecontaining product ( e.g. , beverage overthecounter ( OTC ) medication ) least 24 hour prior day study dosing ; Must willing able remove jewelry treat hand prior day study dosing ; Must willing remove nail polish and/or nail covering treat hand prior day study dosing ; Must donate blood study ; Have adequate finger extension permit application study treatment attachment physiologic measuring instrument . Must willing comply study procedure study visit ; Must provide write informed consent . BMI le 18.5 ; Clinically significant medical abnormality history presence significant neurological , hepatic , renal , endocrine , gastrointestinal , cardiovascular , pulmonary , psychiatric and/or metabolic condition determine Investigator ) ; Clinical diagnosis Systemic Sclerosis association rheumatologic diseases include Mixed Connective Tissue Disease ; Clinically significant abnormal laboratory test result screen determined Investigator ; Raynaud 's Phenomenon think nonsystemic sclerosis etiology ; Peripheral central vasculopathy Systemic Sclerosis ; History Scleroderma renal crisis currently treat hypertension , however , subject control hypertension exclude ; Active digital ulcer rash hand intend study medication ; History past ( 5 ) five year autonomic neuropathy postural hypotension ; Upper extremity sympathectomy level 12 month prior study ; Tobacco smoking within six month screen unwillingness avoid smoking throughout study ( e.g. , cigarette , pipe , cigar , ecigarettes ) use nicotinecontaining product ; Systolic Blood pressure le 85mm/Hg ; Prostanoid use route administration within previous six month ; Current use systemic topical nitrate , endothelin receptor antagonist ( e.g. , bosentan ) longacting PDE5 Inhibitors ( e.g . tadalafil ) ; Use topical corticosteroid hand finger within 10 day screen ; Current use ergot preparation , methysergide , Badrenergic antagonists , contraceptive contain female steroid hormone , cyclosporine , clonidine , nicotine cocaine ; Pregnant lactate female ; Has know exaggerated pharmacological sensitivity hypersensitivity drug similar Alprostadil excipients ; Has know hypersensitivity nitrile ; Involvement investigational drug device study within 30 day prior screen ; History noncompliance treatment clinic visit attendance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Secondary Raynaud 's Phenomenon</keyword>
	<keyword>Secondary Raynaud 's Disease</keyword>
	<keyword>Scleroderma</keyword>
	<keyword>Raynaud 's Disease secondary systemic sclerosis</keyword>
	<keyword>CREST</keyword>
	<keyword>Apricus Biosciences</keyword>
	<keyword>laser doppler</keyword>
	<keyword>thermography</keyword>
</DOC>